Remo Moomiaie-Qajar, M.D.

  • Customizable and active transportation of mRNA-based therapeutics using enucleated synthetic cells (CargocyteTM) to localize therapeutics.
  • Improving mRNA-therapeutic efficacy and safety by localization to the site of disease.
  • Using mRNA loaded Cargocytes as in vivo protein factories in combination with active homing to disease tissues for local drug delivery without systemic, ubiquitous distribution.
  • Next-generation use of mRNA beyond LNP and other passive depositing approaches by active Cargocyte delivery.